Close Menu

NEW YORK (360Dx) – Cambridge, UK-based PredictImmune announced the entry of its first product, PredictSure IBD, into the National Institute for Health and Care Excellence (NICE) Diagnostic Assessment Programme (DAP), an initiative that evaluates new diagnostic technologies and guides people working in the UK's National Health Service in making decisions about adopting them.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.